2021-12-26 H. 教學3F 會議室
時間主題講者座長摘要簡報
09:30 ~ 09:50
瀏覽海報時間
All
09:50 ~ 09:54
MP05-01: The prognostic impact of tumour architecture for upper urinary tract urothelial carcinoma: A propensity score-weighted analysis
劉惠瑛
09:54 ~ 09:58
MP05-02: PR-619, an inhibitor of deubiquitylating enzymes, reverses drug resistance in cisplatin-resistant urothelial carcinoma cells via suppression of c-myc
許富順
09:58 ~ 10:02
MP05-03: Small non-coding microRNAs (miRNAs) target hepatoma-derived growth factor (HDGF) as a novel therapeutic strategy for urothelial carcinoma
孔美蘭
10:02 ~ 10:06
MP05-04: The attenuation of chloroquine and hydroxychloroquine on the invasive potential of bladder cancer by targeting MMP-2 expression
仇光宇
10:06 ~ 10:10
MP05-05: Cadherin-11 regulates cell pyroptosis and induces anti-tumor immunity through PD-L1 in bladder cancer
黃一勝
10:10 ~ 10:14
MP05-06: External validation of Likert scale for predicting non-muscle invasive bladder cancer, KCGMH experience
蔡佳宏
10:14 ~ 10:18
MP05-07: Hyperthermia inhibits chemotherapeutic drug resistance of bladder cancer cells through epithelial mesenchymal transition down-regulation
陳宏恩
10:18 ~ 10:22
MP05-08: Anti-cancer effects and tumor marker role of glutathione s-transferase mu 5 in human bladder cancer
蔡長佑
10:22 ~ 10:26
MP05-09: Glutathione s-transferase Mu 5 plays anti-tumor activity in bladder cancer cells
李亞哲
10:26 ~ 10:30
MP05-10: Results of Bevacizumab plus Erlotinib in Patients with Advanced Papillary Renal Cell Carcinoma (pRCC) Including Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome-Associated RCC
蘇楷森